The Trump administration’s latest Medicare Advantage proposal is less a tweak than a stress test for a program that now covers tens of millions of seniors. By pairing a near‑flat payment update with a crackdown on how plans document patient illnesses, the White House is betting it can squeeze out waste without triggering a backlash from older voters. Whether that gamble pays off will depend on how insurers respond and how quickly any savings are steered back toward beneficiaries instead of balance sheets.
At the center of the fight is not a single eye‑popping number but a pattern: private plans have repeatedly found ways to turn complex billing rules into reliable revenue streams. The new rule aims to shut down one of the most lucrative tactics, even as other corners of Medicare, like high‑priced skin grafts, show how quickly spending can balloon when oversight lags. I see a system trying to close one leak in the hull while new ones keep opening.
The tiny 0.09% raise that rattled a giant market
The Centers for Medicare and Medicaid Services, or CMS, stunned Wall Street by proposing a net average payment increase of just 0.09% for Medicare Advantage plans in 2027. Investors had been counting on something closer to a 4% to 6% bump, so the gap between expectation and reality translated into an immediate market shock. The message from regulators was clear: the era of automatic, generous raises for private Medicare plans is over, at least for now.
The financial hit was not theoretical. A wave of selling wiped roughly $80 billion in market value from major insurers after the proposal landed, a rout that underscored how dependent these companies have become on steady Medicare Advantage growth. One of the most exposed players is Humana, which has built its business model around older Americans and now faces a future where margins are squeezed just as medical costs climb. When a tenth of a percentage point on a federal rate sheet can erase tens of billions of dollars, it shows how tightly the fortunes of corporate giants and federal health policy are intertwined.
Cracking down on “unlinked” chart reviews and upcoding
Behind the modest headline rate lies a more consequential policy shift: CMS is targeting how plans document diagnoses to boost payments. The agency’s proposed 2027 rule would sharply limit the use of “unlinked” chart reviews, where plans scour medical records to add diagnoses that were never part of a face‑to‑face visit, a practice critics say fuels systematic upcoding. Regulators argue that excluding these unverified add‑ons from risk scores will better align payments with actual patient needs rather than coding prowess, a point laid out in detail in the proposed crackdown.
Plans are pushing back hard, warning that curbs on chart reviews will reduce resources for care coordination and supplemental benefits. Jan, an industry voice quoted in coverage of the rule, framed the change as a blunt instrument that punishes plans for trying to capture the full complexity of their members’ health. Yet independent analysts have long warned that diagnosis inflation in Medicare Advantage has driven costs above what comparable patients would generate in traditional Medicare, and the new rule is an attempt to put guardrails around that behavior before it becomes even more entrenched.
From aggressive audits to MedPAC’s $76 billion warning
The proposed chart‑review limits do not come out of nowhere. On May 21, 2025, the Centers for Medicare & Medicaid Services announced a plan “to crush[] fraud, waste, and abuse across” Medicare Advantage, signaling a shift toward more aggressive audits and clawbacks of improper payments. That initiative, described in detail by CMS, laid the groundwork for the current push to tighten documentation rules and recalibrate risk scores.
At the same time, The Medicare Payment Advisory Commission has warned that Medicare Advantage is expected to cost taxpayers $76 billion more this year than if the same beneficiaries were in traditional Medicare. That $76 billion figure is not a rounding error, it is a structural overpayment that filters through to higher Part B premiums for everyone. When I look at the new rule through that lens, the 0.09% increase is less a surprise than a belated response to years of warnings that taxpayers are subsidizing private plans more heavily than policymakers intended.
The Great Healthcare Plan’s political logic
The White House is not shy about the ideological frame behind these moves. The Great Healthcare Plan explicitly promises to stop sending “big insurance companies billions in extra taxpayer‑funded subsidy payments” and instead route that money directly to seniors. That pledge, laid out on the official Great Healthcare Plan site, casts Medicare Advantage reforms as part of a broader effort to curb corporate profits and boost consumer‑facing benefits.
President Donald J. Trump has also called on Congress to enact The Great Healthcare Plan with a focus on LOWERING INSURANCE PREMIUMS for older Americans. The administration argues that by trimming overpayments and tightening audits, it can free up funds that would then be used to reduce premiums and out‑of‑pocket costs, a vision spelled out in a fact sheet that emphasizes sending money “directly to the American people.” The political calculus is straightforward: if seniors see tangible savings, they may be more willing to tolerate turbulence in the private plan market.
What it means for seniors facing higher deductibles
For beneficiaries, the timing is delicate. Medicare Parts A and B premiums and deductibles are already rising, with official tables detailing higher Part B standard premiums and updated Part A Deductible and Coinsurance Amounts for 2026. Those figures, laid out in CMS’s Medicare Parts fact sheet, mean many seniors will pay more before their coverage even kicks in, regardless of which plan they choose.
Layer on top of that the prospect of leaner Medicare Advantage benefits, and the squeeze becomes more apparent. Reporting by Medora Lee for USA TODAY has highlighted warnings that Seniors may face either cuts to their Medicare Advantage benefits or higher costs in 2027 if plans respond to the tiny rate hike by trimming extras or raising premiums. CMS has said it expects to finalize the rule by early April, according to Medora Lee, leaving beneficiaries and insurers a narrow window to adjust before the next plan year.
Open enrollment, plan exits, and the risk of benefit cuts
The pressure will be most visible during Medicare Advantage open enrollment, when seniors compare premiums, networks, and extras like dental or vision coverage. CMS announced in late January that its new policies for Medicare Advantage and Part D are aimed at ensuring payments to insurers more accurately reflect the care they provide, a goal that could translate into tighter margins for plans that have leaned heavily on coding intensity. Analysts have already warned that some insurers may respond by scaling back supplemental benefits, narrowing provider networks, or even exiting certain counties, a concern echoed in open enrollment coverage.
Industry groups argue that flat funding at a time of rising medical inflation will inevitably force trade‑offs that seniors will feel. A statement circulated after the rate announcement said, “Health plans welcome reforms to strengthen Medicare Advantage. However, flat program funding at a time of sharply rising medical costs will result in fewer benefits and higher costs for the 35 million seniors who rely on the program,” a warning captured in rate shock coverage. I read that as both a genuine concern and a negotiating tactic, designed to pressure CMS into sweetening the final rule.
Skin graft spending as a cautionary tale
While the current proposal does not directly target any single service line, the recent surge in spending on skin grafts offers a vivid example of how Medicare dollars can pile up when payment rules are loose. A Report found that Skin graft Medicare spending was estimated to surpass $15B in a single year, with New data showing that the pricey treatments continued to grow rapidly despite questions about their value. That estimate, detailed in a Report, is a reminder that even narrow benefit categories can generate enormous costs when incentives are misaligned.
The lesson for Medicare Advantage is not that all high spending is abusive, but that complex payment systems invite creative billing. If a relatively niche service like skin grafts can reach the $15B mark, it is easy to see why regulators are wary of diagnostic coding practices that quietly ratchet up payments across an entire population. The Trump administration’s focus on unlinked chart reviews is one attempt to get ahead of that dynamic before it produces another runaway spending category.
More From The Daily Overview
*This article was researched with the help of AI, with human editors creating the final content.
Nathaniel Cross focuses on retirement planning, employer benefits, and long-term income security. His writing covers pensions, social programs, investment vehicles, and strategies designed to protect financial independence later in life. At The Daily Overview, Nathaniel provides practical insight to help readers plan with confidence and foresight.
